Routine Form 3 filing for a new insider — no trading activity or material change. Monitor for future Form 4 filings that may indicate open-market purchases or sales.
Price Chart
Executive Summary
Paul Sweetnam filed a Form 3 initial statement of beneficial ownership upon becoming Chief Scientific Officer of Retension Pharmaceuticals, disclosing 402,577 shares of common stock, options to purchase 209,341 shares, and convertible preferred stock holdings. This is a routine insider filing with no material trading or financial impact.
Key Facts
- Paul Sweetnam appointed as Chief Scientific Officer of Retension Pharmaceuticals, Inc.
- Beneficial ownership includes 402,577 shares of common stock (direct).
- Stock options to purchase 80,516 shares at $1.43 (expiring 2034-09-22) and 128,825 shares at $2.43 (expiring 2035-10-30).
- Series A Convertible Preferred Stock convertible into 4,026 shares of common stock (direct).
- Series B Convertible Preferred Stock convertible into 2,640 shares of common stock (held indirectly by spouse).
- Filing is a standard initial ownership report under Section 16(a) for a new officer.
Financial Impact
No financial impact; filing discloses existing holdings of a new officer.
Risk Factors
- No material risks identified from this filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-108140 |
| Document: 0001213900-26-108140-index-headers.html | 0001213900-26-108140 |
| Document: 0001213900-26-108140-index.html | 0001213900-26-108140 |
| Document: 0001213900-26-108140.txt | 0001213900-26-108140 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $15.25 | awaiting T+5 | — | $15.25 (0.00%) |
Oct 16, 2026 10d ago | SC 13G | $16.33 $14.65 | ▼ −10.29% | ▼ −10.14% | $15.25 (−6.61%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $15.25 (+8.39%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $15.25 (+24.90%) |
Oct 14, 2026 12d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $15.25 (+24.90%) |
Oct 13, 2026 13d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $15.25 (+31.01%) |
Oct 13, 2026 13d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $15.25 (+31.01%) |
Oct 9, 2026 17d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $15.25 (+34.72%) |
Oct 9, 2026 17d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $15.25 (+44.82%) |
Oct 8, 2026 18d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $15.25 (+44.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers